Silence Therapeutics said this week that the opposition division of the European Patent Office has upheld an amended version of its core European patent.

The patent, EP 1527176, entitled "Further Novel Forms of Interfering RNA Molecules," claims a double-stranded, blunt-ended RNA capable of inhibiting a target gene, as well as therapeutic uses thereof. It also claims the use of alternating 2’-O-methyl modifications on the molecules.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.